Relative effects of forced vital capacity and ALSFRS-R on survival in ALS.
ALS
ALSFRS-R
PRO-ACT
forced vital capacity
survival
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
27
05
2021
received:
24
08
2020
accepted:
28
05
2021
pubmed:
3
6
2021
medline:
22
9
2021
entrez:
2
6
2021
Statut:
ppublish
Résumé
Amyotrophic lateral sclerosis (ALS) is a degenerative neuromuscular disease with marked clinical heterogeneity. This heterogeneity can be partly captured by clinical measures, such as the forced vital capacity (FVC) and ALS Functional Rating Scale-Revised (ALSFRS-R). We aimed to further characterize the performance of these clinical measures, including their independence and additivity, in predicting mortality. We leveraged the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT ALS) database, which includes data from 23 clinical trials (n = 2050). The primary exposures were baseline FVC and ALSFRS-R. The primary outcome was 1-y mortality. We performed correlation analyses, survival analyses and assessed classification performance using receiver operator characteristic (ROC) curves. FVC and ALSFRS-R were weakly correlated (r = 0.31, p < .001). A 1-SD increase in FVC (hazard ratio [HR]: 0.66; 95% confidence interval [CI]: 0.59-0.74) and ALSFRS-R (HR: 0.75; 95% CI: 0.68-0.82) were associated with reduced risk of 1-y mortality. ROC analyses showed optimal predictive cutoffs at 80% for FVC (area under the curve [AUC]: 0.69) and 38 for ALSFRS-R (AUC: 0.67). After stratifying patients based on these cutoffs, we found a marked reduction (HR: 0.25; 95% CI: 0.19-0.33) in incident mortality for patients in the high FVC and high ALSFRS-R group relative to the low FVC and low ALSFRS-R group. ALSFRS-R and FVC are comparable predictors of survival that are only weakly correlated. When considered together, they synergistically predict survival. As such, consideration of both measures should be a routine part of prognostication in care of patients with ALS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
346-351Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Corcia P, Pradat PF, Salachas F, et al. Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler. 2008;9:59-62. https://doi.org/10.1080/17482960701656940
Chiò A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310-323. https://doi.org/10.3109/17482960802566824
Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162-172. https://doi.org/10.1056/NEJMra1603471
Atassi N, Berry J, Shui A, et al. The PRO-ACT database design, initial analyses, and predictive features. Neurology. 2014;83:1719-1725. https://doi.org/10.1212/WNL.0000000000000951
Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390-392. https://doi.org/10.1136/jnnp.2005.072660
Goyal NA, Berry JD, Windebank A, et al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020;62(2):156-166. https://doi.org/10.1002/mus.26801
Küffner R, Zach N, Norel R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33:51-57. https://doi.org/10.1038/nbt.3051
Daghlas I, Lever TE, Leary E. A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials. Amyotroph Lateral Scler Front Degener. 2018;19:206-211. https://doi.org/10.1080/21678421.2017.1418001
Kueffner R, Zach N, Bronfeld M, et al. Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Sci Rep. 2019;9:1-14. https://doi.org/10.1038/s41598-018-36873-4
Baumann F, Henderson RD, Morrison SC, et al. Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:194-202. https://doi.org/10.3109/17482960902991773
Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13-21. https://doi.org/10.1016/S0022-510X(99)00210-5
Kaufmann P, Levy G, Thompson JLP, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64:38-43. https://doi.org/10.1212/01.WNL.0000148648.38313.64
Javad Mousavi S-A, Zamani B, Shahabi Shahmiri S, et al. Pulmonary function tests in patients with amyotrophic lateral sclerosis and the association between these tests and survival. Iran J Neurol. 2014;13:131.
Mitsumoto H, Garofalo DC, Santella RM, et al. Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2020;21:263-272. https://doi.org/10.1080/21678421.2020.1746810
Calvo A, Vasta R, Moglia C, et al. Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. J Neurol. 2020;267:1615-1621. https://doi.org/10.1007/s00415-020-09751-1
Karanevich AG, Weisbrod LJ, Jawdat O, et al. Using automated electronic medical record data extraction to model ALS survival and progression. BMC Neurol. 2018;18:1-7. https://doi.org/10.1186/s12883-018-1208-z
Schmidt EP, Drachman DB, Wiener CM, Clawson L, Kimball R, Lechtzin N. Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design. Muscle Nerve. 2006;33:127-132. https://doi.org/10.1002/mus.20450
Paganoni S, Nicholson K, Chan J, et al. Urate levels predict survival in amyotrophic lateral sclerosis: analysis of the expanded pooled resource open-access ALS clinical trials database. Muscle Nerve. 2018;57:430-434. https://doi.org/10.1002/mus.25950
Swinscow TDV. Statistics at square one:correlation and regression. BMJ. 1997;75-84.
Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337-344. https://doi.org/10.1111/j.0006-341X.2000.00337.x
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35. https://doi.org/10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
Fluss R, Faraggi D, Reiser B. Estimation of the Youden index and its associated cutoff point. Biom J. 2005;47:458-472. https://doi.org/10.1002/bimj.200410135
Pinto S, de Carvalho M. SVC is a marker of respiratory decline function, similar to FVC, in patients with ALS. Front Neurol. 2019;10:109. https://doi.org/10.3389/fneur.2019.00109
Pinto S, de Carvalho M. Correlation between forced vital capacity and slow vital capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study. Amyotroph Lateral Scler Front Degener. 2017;18:86-91. https://doi.org/10.1080/21678421.2016.1249486
Pirola A, de Mattia E, Lizio A, et al. The prognostic value of spirometric tests in amyotrophic lateral sclerosis patients. Clin Neurol Neurosurg. 2019;184. https://doi.org/10.1016/j.clineuro.2019.105456
Chiò A, Canosa A, Gallo S, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology. 2011;77(15):1432-1437. https://doi.org/10.1212/WNL.0b013e318232ab9b
van Eijk RPA, Westeneng HJ, Nikolakopoulos S, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):e451-e460. https://doi.org/10.1212/WNL.0000000000006855